Tag: GE

New SEMI-NBMC, GE Research Project to Advance Vital Signs Monitoring of Patients During Emergency Air Transport

MILPITAS, Calif., June 22, 2020 /PRNewswire/ — Nano-Bio Materials Consortium (NBMC), a SEMI Strategic Association Partner, today launched a project with GE Research to develop a medical-grade wireless patch that monitors the vital signs of medical patients during emergency air transport. The device promises to advance the state-of-the-art in medical care […]

GE Healthcare Announces U.S. FDA Approval of Macrocyclic MRI Contrast Agent Clariscan™ (gadoterate meglumine) Injection for Intravenous Use

Clariscan, approved in more than 55 countries globally with over four million patient doses shipped, is now FDA-approved in the U.S. Expands the GE Healthcare portfolio of contrast media products CHALFONT ST GILES, England–(BUSINESS WIRE)–The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, […]

GE Healthcare and Lantheus Announce Start of a Phase 3 Clinical Trial of Flurpiridaz, an Investigational Agent Being Evaluated for the Detection of Coronary Artery Disease

BOSTON & NORTH BILLERICA, Mass.–(BUSINESS WIRE)–GE Healthcare and Lantheus Holdings, Inc. (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (collectively “Lantheus”), have started a second Phase 3 clinical trial of Flurpiridaz 18F (called the AURORA study), an investigational agent being evaluated for the detection of coronary artery disease (CAD), the […]

Analytics 4 Life® Expands Its Medical Advisory Board with Global Experts in Cardiology

RESEARCH TRIANGLE PARK, N.C. & TORONTO–(BUSINESS WIRE)–Analytics 4 Life, a digital health company applying the power of artificial intelligence to develop solutions that improve existing care pathways, today announced that it has expanded its Medical Advisory Board with the addition of two global experts in cardiology and digital health. Junbo […]